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ABSTRACT
Oxalates stimulate alterations in renal epithelial cells and thereby induce calcium oxalate (CaOx) stone
formation. Bacillus subtilis YvrK gene encodes for oxalate decarboxylase (OxdC) which degrades oxalate to
formate and CO2. The present work is aimed to clone the oxdC gene in a mammalian expression vector
pcDNA and transfect into Human Embryonic Kidney 293 (HEK293) cells and evaluate the oxdC expression,
cell survival rate and oxalate degrading efficiency. The results indicate cell survival rate of HEK293/
pcDNAOXDC cells pre-incubated with oxalate was enhanced by 28%. HEK293/pcDNAOXDC cells expressing
OxdC treated with oxalate, significantly restored antioxidant activity, mitochondrial membrane potential
and intracellular reactive oxygen species (ROS) generation compared with HEK293/pcDNA. Apoptotic
marker caspase 3 downregulation illustrates HEK293/pcDNAOXDC cells were able to survive under oxalate-
mediated oxidative stress. The findings suggest HEK293 cells expressing oxdC capable of degrading oxalate
protect cells from oxidative damage and thus serve as a therapeutic option for prevention of CaOx stone
disease.
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Introduction
Kidney stone disease is a common, painful condition result from the
combination of epidemiological, biochemical and genetic risk fac-
tors1. Calcium oxalate (CaOx) stones are the most prevalent type,
accounting for 70–80%. Hyperoxaluria is a condition which is associ-
ated with increased excretion of oxalate, a major risk factor for CaOx
urolithiasis. Oxalate accumulation in renal tubular cells contributes
to the progression of renal injury. The interaction between the oxal-
ate crystals and renal cells result in reactive oxygen species (ROS)
generation, and thus play a major role in stone formation. Further,
disruption of the cell membrane can lead to mitochondrial dysfunc-
tion which initiates the cell to form ROS in abundance. Management
of stone disease depends on the size, location and prevailing treat-
ment options have significant drawbacks such as renal damage,
renal impairment and stone recurrence. The use of oxalate-degrad-
ing microorganisms such as Oxalobacter formigenes (O. formigenes)
in the intestines of animals and human beings was focused as an
alternative approach in the prevention of CaOx stone disease.
However, the stable colonization efficiency and antibiotic sensitivity
of O. formigenes in the intestine are still uncertain2. Previous report
revealed the successful insertion of oxalate degrading genes Oxalyl-
CoA decarboxylase (oxc) and formyl-CoA transferase (frc) from O. for-
migenes into human embryonic kidney 293 cells (HEK293) and sug-
gested that these genes are probable prospects for gene therapy3.
Zhiqiang et al.4 have demonstrated the transfer of oxc and frc into
intestinal stem cells to prevent CaOx-related stone formation.
Although the transfected cells showed significant degradation of
oxalate in the medium, the alterations in oxidative stress and sur-
vival efficiency of cells are yet to be analyzed.
The identification of oxalate decarboxylase (oxdC) from Bacillus
subtilis (B. subtilis) proved to be a possible therapeutic option for
calcium oxalate stone disease in human. OxdC can degrade oxal-
ate into formate and carbon dioxide5. Previously, the heterologous
expression of OxdC in Lactobacillus plantarum (L. plantarum) was
developed and utilized as a potential probiotic for depletion of
intestinal dietary oxalate6–8. Since treatment options for patients
with primary hyperoxaluria are limited and the use of recombinant
bacteria is restricted for degradation of intestinal oxalate, an alter-
native approach is required. Hence, the present study is focused
to investigate oxalate degrading efficiency and cell survival ability




HEK293 cells were obtained as a gift from Dr. Giridhara R.
Jayandharan, Indian Institute of Technology, Kanpur, India. The
cells were cultured in Dulbecco’s Modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (Hi-media),
100U/ml penicillin (Hi-media) and 0.1mg/ml streptomycin
(Hi-media) at 37 C in a humidified 5% CO2 atmosphere.
Construction of recombinant vector pcDNAOXDC
The eukaryotic expression vector pcDNA 3.1 (), Invitrogen,
Carlsbad, CA was used for cloning of bacterial gene oxdC. PCR
amplified His tag fused oxdC was cloned in pcDNA vector at Nhe I
and Hind III restriction sites and the resulting recombinant plasmid
pcDNAOXDC was confirmed by PCR, restriction digestion and DNA
sequencing. To evaluate the protein localization of OxdC in
HEK293 cells, eukaryotic expression vector pEGFP-N1 (Clonetech)
was employed to subclone the gene of interest oxdC and trans-
fected in HEK23 cells. The GFP-tagged OxdC protein expression
was visualized using Nikon Eclipse Ti fluorescence microscope
(Nikon, Tokyo, Japan).
Stable transfection of HEK293 cells
Transfection was performed using lipofectamine 3000, Invitrogen,
Carlsbad, CA according to the manufacturer’s instructions.
For stable transfection, cells were selected in DMEM medium con-
taining 0.8mg/ml geneticin (G418, Invitrogen, Carlsbad). The
selective medium was changed every 2–3 days till transfectants
appeared. The clones were screened by semi-quantitative RT-PCR
and confirmed by Western blot analysis using primary mouse
monoclonal antibody against 6x-His Epitope Tag Antibody (1:1000,
Thermo Fischer Scientific) and a primary rabbit polyclonal anti-
body against human ß-actin (1:1000, Santa Cruz). Goat anti-mouse
IgG (1:1000, Santa Cruz) and Goat anti-rabbit IgG conjugated with
HRP (Genei, India) (1:2500) were used as the secondary antibody.
Cytotoxicity assays
Cell viability was evaluated by measuring 3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. Following
treatment of oxalate (750 lM) on recombinant HEK293/pcDNA and
HEK293/pcDNAOXDC cells for 18 h, MTT was added to the medium
(final concentration 0.5mg/ml) and incubated for 4 h in a humidi-
fied atmosphere at 37 C. The media was removed from wells leav-
ing formazone crystals at the bottom which were dissolved in
200 ll of DMSO. Absorbance was recorded at 570 nm immediately.
Optical density values of each well were normalized against the
control wells in which no stress was given. Cytotoxic effect of oxal-
ate on recombinant HEK293/pcDNAOXDC cell proliferation was
determined by trypan blue exclusion assay by harvesting cells
after 18 h. Briefly, the cells were seeded (0.8 105/ml) in plates
and subjected to oxalate stress. Cells were examined under an
optical microscope after trypan blue staining. The percentage of
unstained cells was counted and recorded. On staining cells with
propidium iodide, live and dead cell population was screened
using flow cytometry (BD FACSAria III, BD Biosciences, San Jose)9.
The data were analyzed using FlowJo v X.0.6 software.
Antioxidant profile
After exposure to oxalate, the cells were washed twice with ice
cold PBS and whole cell lysate was prepared by addition of cold
lysis buffer (Tris-Cl and sodium fluoride, 50mM of Tris-Cl; NaCl,
0.15 M; EDTA, 2mM; sodium pyruvate, 1mM; PMSF, 10lg/ml; and
triton-X, 0.1%). The cell lysates were centrifuged at 5000 rpm for
10min and the protein content of the supernatant was estimated
using Bradford reagent (Sigma–Aldrich). Catalase activity was
assayed by the method of Sinha10. The dichromate in the acetic
acid is reduced to chromic acetate when heated in the presence
of hydrogen peroxide. The chromic acetate thus formed was
measured colorimetrically at 570 nm. Results were expressed as
lmol of H2O2 consumed per mg of protein in one minute.
Superoxide dismutase activity was measured by the protocol
developed by Kakkar et al.11. The enzyme assay was based on the
50% inhibition of formation of nicotinamide adenine dinucleotide-
phenazine methosulphate nitroblue tetrazolium formation and the
color developed was read at 520 nm. One unit of enzyme activity
was defined as the amount of enzyme required to give 50%
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inhibition of nitroblue tetrazolium reduction. The lipid peroxida-
tion was determined by estimating malondialdehyde (MDA)12.
Mitochondrial membrane potential
On exposure of recombinant HEK293/pcDNA and HEK293/
pcDNAOXDC cells with oxalate (750 lM for 18 h), alterations
in mitochondrial membrane potential were analyzed using
0.5lM MitoTracker Deep Red, Invitrogen, Carlsbad by flow
cytometry13.
Detection of intracellular ROS generation
In order to detect intracellular ROS generation, recombinant
HEK293/pcDNA and HEK293/pcDNAOXDC cells were treated with
oxalate (750lM) for 18 h. Levels of net intracellular ROS produc-
tion were measured using 2, 7 dichlorodihydrofluorescein diace-
tate (H2DCFDA) by flow cytometry
14.
Gene expression analysis
The mRNA levels of b-actin and Caspase 3 in recombinant
HEK293/pcDNA and HEK293/pcDNAOXDC cells exposed to oxalate
(750 lM for 18 h) were determined with SYBRVR green master mix
(Fermentas, Inc.) using Real-Time Thermal cycler (MastercyclerVR
ep realplex; Eppendorf AG, Germany). The primers used in the
study were adapted from Tian et al.15.
Western blot analysis
The whole-cell proteins (20 lg) of recombinant HEK293/pcDNA
and HEK293/pcDNAOXDC cells exposed to oxalate (750 lM for
18 h) were solubilized in the sample buffer, separated using SDS-
PAGE and transferred to PVDF membrane. The membrane was
blocked and exposed to primary rabbit polyclonal antibodies (anti-
Caspase 3, 1:500) (Pierce) overnight at 4 C. The membrane was
washed and incubated with the HRP-conjugated anti-rabbit IgG
(1:2500) (Genei, India) for 60min and was detected with
Amersham ECL Western blotting reagent (GE healthcare Life
Sciences). The blot was scanned using Bio-Rad Gel Doc XR and the
intensity of protein bands normalized to b Actin was quantified
using Image Lab Software version 5 (Bio-Rad).
Oxalate degrading ability
The enzyme activity of OxdC was assayed by determining the
change of oxalate concentration in the medium. Following recom-
binant HEK293/pcDNA and HEK293/pcDNAOXDC cells cultured for
48 h at 37 C, the medium was replaced with DMEM supplemented
with 750lM of potassium oxalate. Subsequently, the growth
medium was collected at different time points (0, 6, 12, 18, 24,
48 h) and filtered. The cell free extracts were analyzed for oxalate
by using a commercially available enzymatic kit (Trinity Biotech).
Statistical analysis
All the grouped data were statistically evaluated with SPSS
Statistics Version 19 software. Statistically significant differences
between samples were determined by one-way ANOVA followed
by Least Significant Difference (LSD) post-hoc analysis. Data were
presented as mean± standard deviation (SD). Results were consid-
ered significant if p values <0.05.
Results
Stable transfection of HEK293 cells with pcDNAOXDC
Recombinant plasmid pcDNA-OXDC and vector pcDNA were trans-
fected into HEK293 cells by lipofection. The integration of oxdC in
the cell was demonstrated by semi-quantitative RT-PCR (Figure 1A)
and OxdC protein expression (44 kDa) was confirmed by
Western blot (Figure 1B). The recombinant OxdC protein secreted
into the supernatant of transfected cell lines was quantified to be
26.3 lg/ml. The fluorescence tagged protein OxdC was observed in
the cytoplasm of HEK293 cells (Figure 1C,D)
Heterologous OxdC augment cell viability in oxalate induced
toxicity
We investigated the effect of oxdC on proliferation and survival of
cells. Results illustrated that the cell viability was significantly
affected in recombinant HEK293 cells devoid of oxdC after 18 h of
oxalate treatment. The cytotoxic effect of oxalate was limited in
recombinant HEK293/pcDNAOXDC cells. MTT assay revealed
HEK293/pcDNAOXDC cells showed enhanced cell viability (28%)
(Figure 1E,F) compared with HEK293/pcDNA cells. Figure 1(G,H)
shows the cells expressing OxdC exhibited significantly higher lev-
els (24%) of survival ability (p< 0.05) than cells devoid of OxdC.
Ameliorative effect of OxdC on antioxidant enzyme markers
Catalase and superoxide dismutase activities were significantly
reduced in HEK293/pcDNA cells treated with oxalate when com-
pared with non-exposed cells (Table 1). However, no significant
alteration in catalase activity was observed in HEK293/
pcDNAOXDC cells. Superoxide dismutase activity was significantly
increased in recombinant HEK293/pcDNAOXDC cells compared to
HEK293/pcDNA cells with oxalate. As a consequence of oxidative
stress, the concentration of MDA was significantly increased by
60% in HEK293/pcDNA cells. On the contrary, the MDA level in
recombinant HEK293/pcDNAOXDC cells was significantly lower
than HEK293/pcDNA cells pre-incubated with oxalate (Table 1).
Assessment of mitochondrial membrane potential
Oxalate exposure to HEK293 cells modulated mitochondrial mem-
brane potential. Recombinant HEK293 cells expressing OxdC
showed increased membrane potential when compared to
HEK293/pcDNA cells treated with oxalate. Maximum mean fluores-
cence intensity was observed in HEK293/pcDNA cells not
subjected to oxalate (Figure 2A,B).
OxdC expression reduce the ROS generation
On exposure to oxalate, recombinant HEK293 cells expressing
OxdC showed significantly decreased ROS generation (45.5%)
when compared with HEK293 cells devoid of OxdC (76.33%)
(p< 0.05) (Figure 2C,D).
OxdC protect cells from apoptosis
HEK293/pcDNA cells pre-incubated with oxalate showed significant
upregulation of apoptotic marker caspase 3 when compared with
HEK293/pcDNA cells devoid of oxalate stress. The recombinant
HEK293/pcDNAOXDC cells pre-incubated with oxalate, exhibited
significant reduction of caspase 3 mRNA and protein expression in
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Figure 1. (A) Expression of oxdC gene in HEK 293 cells, confirmed by Semi-quantitative PCR. Lane M, 1 kb ladder; lane 1, Empty vector; lanes 2, 3, 4, 5, 1.2 kb amplified
product of oxdC. (B) The results of protein immunoblot analysis. Lane 1, HEK293 cells, lane 2, HEK293/pcDNA cells, lane 3, HEK293/pcDNAOXDC expressed protein corre-
sponding to size 44 kDa detected in the stably transfected cells. (C) HEK293 cells were transfected with pEGFP-N1 (empty vector) and (D) pOXDC-EGFP. At 48 h, pEGFP-
N1 (empty vector) and pOXDC-EGFP transfected cells exhibited bright green fluorescence and fusion proteins (OXDC-EGFP) were located in the cytoplasm. (E) Cell viabil-
ity of HEK293/pcDNA and HEK293/pcDNAOXDC cells exposed to oxalate (750lM for 18 h) was determined by MTT assay. (F) Trypan Blue Exclusion assay for determin-
ation of cytotoxicity effect of oxalate stress. (G) Live and dead cell population of HEK293/pcDNAOXDC following exposure to oxalate stress by flow cytometry analysis.
(H) Bar diagram shows the % of live and dead cells following oxalate treatment. Each experiment was repeated a minimum of three independent times. Continuous
line – HEK293/pcDNA (No stress); Dotted line – HEK293/pcDNA (Oxalate stress); Dashed line – HEK293/pcDNAOXDC (Oxalate stress). a – significant difference from
HEK293/pcDNA cells without oxalate stress. b – significant difference from HEK293/pcDNA cells with oxalate stress. Values are statistically significant at p< 0.05.
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comparison with HEK293/pcDNA cells exposed to oxalate
(p< 0.05) (Figure 3A–C).
Oxalate degrading ability by recombinant HEK293 cells
expressing heterologous OxdC
Figure 4 demonstrates a significant reduction of oxalate level in
the medium of recombinant HEK293 cells harboring pcDNAOXDC
while oxalate reduction was not observed in recombinant
HEK293/pcDNA cells. The oxalate concentration was reduced to
348 lM in the medium of recombinant HEK293/pcDNAOXDC cells.
The reduction of oxalate in the medium of HEK293/pcDNAOXDC
was a consequence of OxdC.
Discussion
Oxalate is a toxic non-essential end product of metabolism and is
excreted unchanged in urine and feces. There is no known natur-
ally occurring enzyme in humans capable of degrading or metabo-
lizing oxalate, nevertheless, it is catabolized by a limited number
of bacterial species to formate and carbon dioxide. Evidences
Table 1. The antioxidant profile of recombinant HEK293/pcDNAOXDC and HEK293/pcDNA cells when exposed to 750 lM of oxalate stress for 18 h.
Antioxidant profile
Recombinant HEK293/
pcDNA without oxalate stress
Recombinant HEK293/
pcDNA with oxalate stress
Recombinant HEK293/
pcDNAOXDC with oxalate stress
Catalase (lmol of H2O2 consumed/min/mg) 31.63 ± 2.29 16.39 ± 1.38 30.97 ± 2.3†
Superoxide dismutase (U/mg protein) 3.31 ± 0.23 1.29 ± 0.09 2.03 ± 0.4,†
Lipid peroxidation (nmol/mg protein) 1.45 ± 0.07 3.76 ± 0.16 2.48 ± 0.16,†
SOD: one enzyme unit was expressed as inverse of the amount of protein (mg) required for inhibiting reduction rate by 50% in 1min. Values are stat-
istically significant at p< 0.05.Significant difference from HEK293/pcDNA cells without oxalate stress.
†Significant difference from HEK293/pcDNA cells with oxalate stress.
Figure 2. (A, B) – Histogram and bar diagram representation of mitochondrial membrane potential in HEK293/pcDNA and HEK/pcDNAOXDC cells following exposure to
oxalate (750lM) for 18 h. (C, D) – Histogram representation and bar diagram of oxalate on ROS production in HEK293/pcDNA and HEK/pcDNAOXDC cells. Each experi-
ment was repeated a minimum of three independent times. Continuous line – HEK293/pcDNA (No stress); Dotted line – HEK293/pcDNA (Oxalate stress); Dashed line –
HEK293/pcDNAOXDC (Oxalate stress). a – significant difference from HEK293/pcDNA cells without oxalate stress. b – significant difference from HEK293/pcDNA cells
with oxalate stress. Values are statistically significant at p< 0.05.
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suggested that O. formigenes is associated with a decrease in urin-
ary oxalate excretion owing to degradation of oxalate in the gut
leading to reduced absorption. However, previous report demon-
strated that the intestinal colonization of O. formigenes was not
successfully accomplished in most patients16, thus potentially lim-
iting its usage. The identification of OxdC from B. subtilis has been
proved to be a possible therapeutic option for calcium oxalate
stone disease in human. Therefore, the present work is an attempt
to analyze the oxalate degrading efficiency of heterologous OxdC
in HEK293 cells.
The results of the present study revealed recombinant
HEK293 cells expressing OxdC exhibited higher cell viability than
cells that were devoid of OxdC when exposed to oxalate stress.
The loss in cell viability when exposed to oxalate stress can be
attributed to ROS generation. The accumulation of highly react-
ive oxygen radicals alters enzyme activities and exerts deleteri-
ous effect on membrane. The overproduction of ROS leads to
the reduction in endogenous antioxidant function that eventu-
ally causes development of oxidative stress17. Several enzymes
play a decisive role in reducing oxidative damage by scavenging
ROS as cellular antioxidant system. HEK293/pcDNA cells incu-
bated with oxalate caused decrease in activities of catalase
(CAT) and superoxide dismutase (SOD) by about 2 and 2.5 fold
respectively, which are concordant with earlier report18. The
results indicate CAT and SOD activities in HEK293 cells were sig-
nificantly inhibited by oxalate whereas OxdC presence in
HEK293 cells reversed the enzymatic changes suggesting the
cytoprotective effect of recombinant HEK293/pcDNAOXDC cells.
Zhai et al.19 and Farooq et al.20 have revealed that the use of
exogenous antioxidants conferred a protective role in oxalate
stress. Oxalate provokes ROS generation that in turn causes dis-
ruption of cell membranes as a result of lipid peroxidation.
Oxalate exposure to HEK293/pcDNA cells showed elevated intra-
cellular MDA levels by 1.7 fold. However, a significant decrease
of MDA levels observed in HEK293/pcDNAOXDC cells pre-incu-
bated with oxalate indicates the cells are protected from oxida-
tive damage. Renal injury and inflammation caused by ROS play
a major role in stone formation. Previous reports suggested that
OxdC isolated and purified from B. subtilis exhibited activity in
the range of pH 3 to 7 with an optimal activity at pH 55,21.
The present results showed that 54% reduction of oxalate in
the medium of recombinant HEK293 cells harboring
pcDNAOXDC. This suggest that heterologous enzyme OxdC to
be biologically active in HEK293 cells. Since OxdC localization
occurs in the cytoplasm, oxalates enter the cell and are
Figure 3. (A) Relative gene expression analysis of caspase 3 in HEK293/pcDNAOXDC and HEK293/pcDNA exposed to oxalate stress (750lM, 18 h). (B,C) Relative protein
expression of caspase 3 in HEK293/pcDNAOXDC and HEK293/pcDNA exposed to oxalate stress (750lM, 18 h). a – significant difference from HEK293/pcDNA cells with-
out oxalate stress. b – significant difference from HEK293/pcDNA cells with oxalate stress. Values are statistically significant at p< 0.05.
Figure 4. Oxalate degrading ability of recombinant HEK293/pcDNAOXDC and
HEK293/pcDNA cells in oxalate rich medium (750lM) at different time intervals.
The represented data are mean value of three independent experiments.
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effectively degraded to formate and CO2, thereby protect the
cell from oxalate-mediated oxidative stress induced damage.
Earlier studies have elucidated the abrasive effects of both oxal-
ate and CaOx crystals in renal epithelial cell injury through free
radicals22,23. ROS generation increases in response to renin angio-
tensin system activation and eventually causes mitochondrial dam-
age24. Zhai et al.19 demonstrated that ROS generation from the
intramembrane compartment of mitochondria promotes injury to
renal tubular cells. Cytochrome C released from the mitochondria
binds to cytosolic apoptosis protease activating factor 1 and
thereby activates caspase 9 and caspase 3, which results in the ini-
tiation of apoptosis. In concordant with earlier reports, our results
indicate that oxalate stress led to decrease in mitochondrial mem-
brane potential that may incite the release of Cytochrome C from
the mitochondria resulting in the activation of caspase cascade
and subsequently apoptosis20,24,25. Caspases are crucial mediators
for programmed cell death and caspase 3 plays a vital role in both
intrinsic and extrinsic apoptotic pathway. In comparison to earlier
reports, the present study revealed caspase 3 upregulation on
exposure of HEK293/pcDNA cells to oxalate19,20. On the contrary,
Patel et al.26 had reported no significant change in caspase 3
activity on exposure of calcium oxalate monohydrate crystals in
renal epithelium cells. Interestingly in our study, HEK293/
pcDNAOXDC cells showed significant decrease in caspase 3
expression. These results provide evidence that oxalate-mediated
apoptosis is prevented in HEK293/pcDNAOXDC cells. Although the
administration of bioflavonoids restored antioxidant activity,
subdued ROS generation and decreased caspase 3 expression in
NRK-52E cells19, the degradation of oxalate can prove to be an
alternative therapeutic possibility for patients exhibiting
hyperoxaluria.
In our study, the heterologous OxdC protein expression
enabled in reduction of oxalate stress thus provided a favorable
environment for cell survival. The presence of OxdC in recombin-
ant HEK293 cells confers protection against oxidative stress
through the reduction of oxalate concentration in the medium
that consequently decreases ROS generation. Poljsak27 suggested
that the first-line of defense in quenching ROS-mediated apoptosis
is by eliminating exogenous ROS generating pollutants from the
milieu. The interaction involving CaOx crystals and oxalate ions
with renal tubular epithelium may enhance urinary calculi forma-
tion28. Therefore, the reduction of oxalate ions and oxalate-medi-
ated oxidative stress are possible therapeutic options for the
prevention and treatment of CaOx stone disease. The present
study indicates recombinant HEK293 cells expressing OxdC can
notably contribute in protecting the cell from apoptosis by
degrading the oxalate in the medium. The transfection of oxdC
enabled the HEK293 cell lines to acquire oxalate degrading ability.
The presence of oxdC gene can mitigate the oxalate stress;
thereby protect the cell from oxalate ion-mediated oxidative dam-
age. The development of stable transfectant with oxalate degrad-
ing efficacy can provide new insights into the treatment of
hyperoxalauria and CaOx kidney stone disease.
Conclusions
Oxalate-mediated renal injury may promote stone formation by
providing cellular debris for CaOx crystal nucleation and aggrega-
tion. Our results demonstrate that recombinant HEK293/
pcDNAOXDC cells can ameliorate oxalate stress and thereby confer
protection against oxidative damage resulting from oxalate ions.
Hence, the reduction of oxalate induced oxidative stress can prove
to be a possible therapeutic option for the prevention of CaOx
stone disease. Despite recombinant HEK293/pcDNAOXDC cells
showed significant efficiency in degradation of oxalate in vitro,
experimental based in vivo model is required to demonstrate the
feasibility of our approach.
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